Sign in Subscribe

crc-research

A collection of 715 issues

Review Outlines Advances and Challenges to Colonoscopy Quality

Skip to content The CRC Digest ▪ SCREENING Review Outlines Advances and Challenges to Colonoscopy Quality A new article in Gastrointestinal Endoscopy Clinics of North America outlines current advances, challenges, and best practices for high-quality colonoscopy, noting that colorectal cancer remains the third most common cancer by incidence and second most

Age-Stratified Mutation Patterns Reveal Distinct Features in Early-Onset CRC

Skip to content The CRC Digest ◇ RESEARCH Age-Stratified Mutation Patterns Reveal Distinct Features in Early-Onset CRC Analysis of 6,762 samples across four age groups found that early-onset colorectal cancer (diagnosed before age 50) shows different mutation patterns compared to later-onset disease, with implications for testing guidelines and therapeutic development.

Dual Oral Regimen Shows Activity in KRAS G12C–Mutated Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Dual Oral Regimen Shows Activity in KRAS G12C–Mutated Metastatic CRC A phase Ib/II trial evaluated the chemotherapy-free combination of ifebemtinib (a FAK inhibitor) plus garsorasib (a KRAS G12C inhibitor) in previously treated KRAS G12C–mutated metastatic colorectal cancer, showing encouraging antitumor

CRC Research Update — September 04, 2026

Today's colorectal cancer research highlights

Vietnamese Cohort Compares Early- vs Late-Onset CRC Outcomes

Skip to content The CRC Digest Vietnamese Cohort Compares Early- vs Late-Onset CRC Outcomes A retrospective study of 486 patients who underwent curative resection in Vietnam's Mekong Delta compared clinicopathologic features and survival between early-onset and late-onset colorectal cancer. (Arq Bras Cir Dig) This content is informational only

Risk Factors for Early-Onset CRC Reviewed

Skip to content The CRC Digest Risk Factors for Early-Onset CRC Reviewed A clinical review highlights that early-onset CRC (diagnosed before age 50) arises from both nonmodifiable factors (age, family history, race/ethnicity) and modifiable factors (obesity, diet, inactivity, alcohol, tobacco). (Gastrointest Endosc Clin N Am) This content is informational

Nanoparticle Platform Targets Radioresistance in KRAS-Mutant CRC

Skip to content The CRC Digest ◇ RESEARCH Nanoparticle Platform Targets Radioresistance in KRAS-Mutant CRC Researchers developed sulfasalazine-loaded hafnium oxide nanoparticles (HfO2@SAS) to overcome radiotherapy resistance in KRAS-mutant colorectal cancer by targeting the SLC7A11/GPX4 pathway and inducing ferroptosis (a form of cell death). (Biomaterials) This content is informational only

Meta-Analysis Examines Fecal Immunochemical Test Accuracy

Skip to content The CRC Digest ▪ SCREENING Meta-Analysis Examines Fecal Immunochemical Test Accuracy A systematic review and meta-analysis evaluated the diagnostic accuracy of quantitative fecal immunochemical tests (FIT) for colorectal cancer and advanced neoplasm, examining variations in performance by sex, geographic region, study design, FIT platform, and positivity threshold. (Cancer

Blood-Based CRC Screening Tests Show Promise but Have Key Limitations

Skip to content The CRC Digest ▪ SCREENING Blood-Based CRC Screening Tests Show Promise but Have Key Limitations Three blood-based CRC screening tests (Epi proColon, Shield, and the Freenome test) have completed large validation studies, but all show low sensitivity for advanced precancerous lesions, low rates of follow-up colonoscopy after an

Early-Onset Colorectal Cancer Incidence Accelerates Through 2023

Skip to content The CRC Digest ▪ SCREENING Early-Onset Colorectal Cancer Incidence Accelerates Through 2023 SEER data show early-onset CRC incidence accelerated during 2019-2023 with an annual percent change of 8.3%, while incidence among adults 65 and older declined. Black patients more often presented with stage IV disease (33.9%